![Joël Jean-Louis Besse](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Joël Jean-Louis Besse
Plus aucun poste en cours
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Ignacio Faus | M | - |
NFL Biosciences SAS
![]() NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 ans |
Axel Ullrich | M | - |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
François Cadène | M | - |
Pharma Group Santé SAS
![]() Pharma Group Santé SAS Medical DistributorsDistribution Services Pharma Group Santé SAS develops pharmaceutical dispensation solutions. It offers training and product promotion services. The company was founded by François Cadène in 2000 and is headquartered in Marseille, France. | 24 ans |
Yannick Plétan | M | - |
NFL Biosciences SAS
![]() NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 ans |
Francis Ahner | M | - |
NFL Biosciences SAS
![]() NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 ans |
Michel Huc | M | - |
NFL Biosciences SAS
![]() NFL Biosciences SAS BiotechnologyHealth Technology NFL Biosciences SAS is a biotechnology company, which engages in the development of botanical drug candidates for the treatment of tobacco addiction and neurological diseases. Its pipeline includes NFL-101 tobacco extract; NFL-201 cannabis and tobacco extract; and NFL-301 botanical extract. The company was founded by Bruno Lafont and Jean-Pierre Nicolas in September 2006 and is headquartered in Castelnau-le-Lez, France. | 3 ans |
Johannes Bange | M | - |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Junichi Fukute | M | - |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Esther Zwick | F | - |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Mauricio Redondo | M | - |
U3 Pharma AG
![]() U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Statistiques
Pays | Relations | % du total |
---|---|---|
Allemagne | 5 | 50,00% |
France | 5 | 50,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Joël Jean-Louis Besse
- Réseau Personnel